Literature DB >> 15302607

A common polymorphism in the promoter of the IGF-I gene associates with increased fasting serum triglyceride levels in glucose-tolerant subjects.

Eva-Maria D Nielsen1, Lars Hansen, Maria Lajer, Kirstine L Andersen, Søren M Echwald, Søren A Urhammer, Torben Hansen, Oluf Pedersen.   

Abstract

OBJECTIVE: The aim of the present study was to examine if absence of a common allele in a microsatellite polymorphism in the insulin-like growth factor I (IGF-I) promoter was associated with type 2 diabetes and alterations in quantitative traits in glucose-tolerant subjects.
METHODS: The IGF-I promoter polymorphism was investigated in a case-control study comprising 694 type 2 diabetic patients and 218 glucose-tolerant control subjects, and in two genotype-quantitative trait studies involving 208 glucose-tolerant first-degree offspring of type 2 diabetic patients and 218 unrelated middle-aged subjects with normal glucose tolerance.
RESULTS: No associations were found between the lack of the common promoter allele and type 2 diabetes (P = 0.25) or estimates of glucose metabolism in glucose-tolerant subjects. Presence of the wild-type allele was associated with an increase in fasting serum triglyceride levels in the group of 208 glucose-tolerant first-degree offspring of type 2 diabetic patients (P = 0.002). This finding was replicated in an independent sample of 218 unrelated middle-aged subjects with normal glucose tolerance (P = 0.007).
CONCLUSION: The present study provides evidence that the common wild-type allele of the IGF-I promoter polymorphism is associated with increased levels of fasting serum triglyceride in glucose-tolerant whites.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15302607     DOI: 10.1016/j.clinbiochem.2004.03.014

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  6 in total

1.  Impaired skeletal growth in mice with haploinsufficiency of IGF-I: genetic evidence that differences in IGF-I expression could contribute to peak bone mineral density differences.

Authors:  S Mohan; D J Baylink
Journal:  J Endocrinol       Date:  2005-06       Impact factor: 4.286

Review 2.  Molecular genetics of human growth hormone, insulin-like growth factors and their pathways in common disease.

Authors:  Santiago Rodriguez; Tom R Gaunt; Ian N M Day
Journal:  Hum Genet       Date:  2007-05-30       Impact factor: 4.132

3.  Investigation of the Interplay between Circulating Lipids and IGF-I and Relevance to Breast Cancer Risk: An Observational and Mendelian Randomization Study.

Authors:  Vanessa Y Tan; Caroline J Bull; Kalina M Biernacka; Alexander Teumer; Tom G Richardson; Eleanor Sanderson; Laura J Corbin; Tom Dudding; Qibin Qi; Robert C Kaplan; Jerome I Rotter; Nele Friedrich; Uwe Völker; Julia Mayerle; Claire M Perks; Jeff M P Holly; Nicholas J Timpson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-09-28       Impact factor: 4.090

4.  Insulin-like growth factor 1 gene (CA)n repeats and a variable number of tandem repeats of the insulin gene in Brazilian children born small for gestational age.

Authors:  Rocio R D Coletta; Alexander A L Jorge; Catarina Brasil D'Alva; Emília M Pinto; Ana Elisa C Billerbeck; Paulo R Pachi; Carlos A Longui; Ricardo M Garcia; Margaret Boguszewski; Ivo J P Arnhold; Berenice B Mendonca; Elaine M F Costa
Journal:  Clinics (Sao Paulo)       Date:  2013-06       Impact factor: 2.365

5.  IGF1 Gene Is Associated With Triglyceride Levels In Subjects With Family History Of Hypertension From The SAPPHIRe And TWB Projects.

Authors:  Wen-Chang Wang; Yen-Feng Chiu; Ren-Hua Chung; Chii-Min Hwu; I-Te Lee; Chien-Hsing Lee; Yi-Cheng Chang; Kuan-Yi Hung; Thomas Quertermous; Yii-Der I Chen; Chao A Hsiung
Journal:  Int J Med Sci       Date:  2018-06-14       Impact factor: 3.738

6.  miR‑181d promotes cell proliferation via the IGF1/PI3K/AKT axis in glioma.

Authors:  Dong Tang; Wenhong Gao; Jian Yang; Junhui Liu; Jian Zhao; Jian Ge; Qianxue Chen; Baohui Liu
Journal:  Mol Med Rep       Date:  2020-08-26       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.